AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04423211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given SC
Study NCT04423211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT04951232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinepazide Maleate
Description: The experimental group: guipiprazitel maleate injection (klingo): 320mg (4), dissolved in 500ml of normal saline, and injected in a medium vein at a rate of 100ml/h, once a day, and administered for 14 days.
Study NCT04951232 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 4 pieces, dissolved in normal saline 500ml, intravenous drip, the speed is 100ml / h, once a day, continuous administration for 14 days
Study NCT00144027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication adherence intervention
Description: The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
Study NCT01733069 — intervention group
Intervention type: DEVICE
Intervention: APTIMA COMBO 2 Assay (AC2 Assay)
Description: APTIMA COMBO 2 Assay (AC2 Assay
Study NCT04530812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Maintain usual diet
Study NCT04530812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kefir
Description: Consume commercial kefir beverage
Study NCT04530812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04530812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04530812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04530812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04423211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Proton Therapy
Description: Undergo IMPT
Study NCT04423211 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT04423211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT04423211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT04423211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MR
Study NCT04423211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MR
Study NCT04423211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT or PET/MR
Study NCT04423211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT or PET/MR
Study NCT04423211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04423211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04423211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04423211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04423211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relugolix
Description: Given PO
Study NCT04423211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO
Study NCT04423211 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT04423211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Given IM
Study NCT04423211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Given IM
Study NCT04488692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early intervention (Mobility functional training)
Description: functional training focused on mobility (bed mobility, sitting balance, standing balance, and ambulation)
Study NCT04488692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early intervention (Mobility functional training)
Description: functional training focused on mobility (bed mobility, sitting balance, standing balance, and ambulation)
Study NCT04488692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham intervention
Description: friendly visit and education
Study NCT04423211 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volume Modulated Arc Therapy
Description: Undergo VMAT
Study NCT03213704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03213704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo a bone marrow aspiration and/or biopsy
Study NCT03213704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo a bone scan
Study NCT03213704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT03213704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib Sulfate
Description: Given PO or via nasogastric- or gastric-tube
Study NCT03213704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03213704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo a MIBG scintigraphy
Study NCT03394664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeding Study
Description: Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).
Study NCT02114008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic examinations
Description: Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test) and after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin). All patients received both oral and written information about the protocol at the outpatient clinic.
Study NCT03542240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 500 milligram daily supplement
Study NCT01892254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, 2x 2 tablets a day, 500 mg tablets
Study NCT01892254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin, 2x 2 tablets a day, 500 mg tablets
Study NCT01892254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (to metformin)
Study NCT01892254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (to metformin)
Study NCT03333785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eOncoNote
Description: * Diagnosis phase: The patient's nurse navigator will initiate an eOncoNote to the patient's PCP, inviting them to send any questions related to the patient's diagnostic process. The nurse navigator will initiate case closure after the diagnostic process has been completed (case will be open up to 4 months).~* Treatment phase: The patient's medical or radiation oncologist will initiate an eOncoNote to the patient's PCP inviting them to ask questions related to the patient's cancer treatment and/or request information related to the patient's co-morbidities. The oncologist will initiate case closure after the treatment has been completed.~* Survivorship phase: The patient's registered nurse within the Wellness Beyond Cancer Program will send an eOncoNote invitation to the patient's PCP inviting them to ask any questions as the patient transitions back to their care. The nurse will initiate case closure after one year.
Study NCT01792622 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
Study NCT01792622 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
Study NCT01641016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
Study NCT01641016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
Study NCT03593304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection Mecobalamin
Description: Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
Study NCT03593304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Pyridoxine hydrochlorid
Description: Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
Study NCT03593304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
Study NCT03593304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
Study NCT01626638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal Micro Endoscopy
Study NCT01812590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT02602977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple-dose Remote Ischemic Preconditioning
Description: A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Multiple-dose RIPC consists of a daily dose of 1 RIPC as described above for 7 consecutive days.
Study NCT02602977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-dose Remote Ischemic Preconditioning
Description: A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Single-dose RIPC consists of 1 dose of RIPC as described above
Study NCT02602977 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LPS infusion
Description: To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group \[n=10\], single-dose RIPC group \[n=10\] and control group \[n=10\]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
Study NCT02602977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS infusion
Description: To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group \[n=10\], single-dose RIPC group \[n=10\] and control group \[n=10\]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
Study NCT01936077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant LH (Luveris)
Description: 150 IU recombinant LH daily.
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bactrim
Description: All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).
Study NCT00023244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bactrim
Description: All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).
Study NCT04672330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) before surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）
Study NCT02250027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL301 300mg capsule
Description: 2 capsules at once, 3 times a day, for 7 days
Study NCT03213704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study NCT01070550 — intervention group
Intervention type: DRUG
Intervention: Peginterferon alfa-2a (Pegasys®)
Description: Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Study NCT00818142 — intervention group
Intervention type: BEHAVIORAL
Intervention: ED/DM Support Group
Description: The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
Study NCT03830801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVLCM tethered capsule
Description: Obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk using IVLCM tethered capsule
Study NCT00500149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyvanse (lisdexamfetamine dimesylate)
Description: Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).
Study NCT00500149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02298517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: incentive spirometry
Description: Incentive spirometry to flow and incentive spirometry to volume
Study NCT01712685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-VM4-037
Description: Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.
Study NCT01712685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Study NCT00486915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left Atrial Appendage Ligation
Study NCT00180674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study NCT03034317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuRx DPS
Description: Patients who are diagnosed with ALS, have initiated NIV and choose to have the NeuRx DPS implanted.
Study NCT01472627 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draws
Description: Blood draws
Study NCT04428086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib in arm1
Description: Apatinib will be administered at a dose of 250 mg once daily from Day 4 to Day 9.
Study NCT04428086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 7.
Study NCT04428086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib in arm2
Description: Apatinib will be administered at a dose of 250 mg once daily from Day 3 to Day 7.
Study NCT04428086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered as a single oral 500 mg on Day 1 and Day 6.
Study NCT02937844 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 CSR T cells
Description: Prescribed CSR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）.
Study NCT02937844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m\^2, d1-3